KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$5.6 million.

  • Neogenomics' Change in Inventory fell 55309.73% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 52393.44%. This contributed to the annual value of $2.7 million for FY2024, which is 49449.34% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Change in Inventory is -$5.6 million, which was down 55309.73% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Change in Inventory peaked at $4.1 million during Q2 2025, and registered a low of -$5.6 million during Q3 2025.
  • For the 5-year period, Neogenomics' Change in Inventory averaged around $217578.9, with its median value being $449000.0 (2021).
  • Over the last 5 years, Neogenomics' Change in Inventory had its largest YoY gain of 103415.84% in 2024, and its largest YoY loss of 201800.0% in 2024.
  • Neogenomics' Change in Inventory (Quarter) stood at $1.6 million in 2021, then crashed by 55.38% to $697000.0 in 2022, then plummeted by 71.02% to $202000.0 in 2023, then soared by 1034.16% to $2.3 million in 2024, then tumbled by 345.83% to -$5.6 million in 2025.
  • Its Change in Inventory was -$5.6 million in Q3 2025, compared to $4.1 million in Q2 2025 and $3.0 million in Q1 2025.